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The cytoskeleton adaptor protein ankyrin-1 is
upregulated by p53 following DNA damage and alters
cell migration
AE Hall1, W-T Lu1, JD Godfrey1, AV Antonov1, C Paicu2,3, S Moxon2, T Dalmay4, A Wilczynska1, PAJ Muller1 and M Bushell*,1
The integrity of the genome is maintained by a host of surveillance and repair mechanisms that are pivotal for cellular function. The
tumour suppressor protein p53 is a major component of the DNA damage response pathway and plays a vital role in the
maintenance of cell-cycle checkpoints. Here we show that a microRNA, miR-486, and its host gene ankyrin-1 (ANK1) are induced by
p53 following DNA damage. Strikingly, the cytoskeleton adaptor protein ankyrin-1 was induced over 80-fold following DNA
damage. ANK1 is upregulated in response to a variety of DNA damage agents in a range of cell types. We demonstrate that
miR-486-5p is involved in controlling G1/S transition following DNA damage, whereas the induction of the ankyrin-1 protein alters
the structure of the actin cytoskeleton and sustains limited cell migration during DNA damage. Importantly, we found that higher
ANK1 expression correlates with decreased survival in cancer patients. Thus, these observations highlight ANK1 as an important
effector downstream of the p53 pathway.
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Cells respond to DNA damage by orchestrating a series of
events, either resulting in cell-cycle arrest and DNA repair, or
elimination of the damaged cell. DNA double-strand breaks
(DSB) are one of the most toxic types of DNA damage
experienced by cells.1 A complex network of mechanisms has
evolved to detect and repair DSBs. DNA repair is achieved
either via non-homologous end-joining or in a more accurate
manner by homologous recombination.2 Failure of either of
these mechanisms triggers apoptosis.3
The DNA damage response pathway (DDR) involves a
cascade of eventswith multiple effector components,3–7 key to
which is the tumour suppressor protein p53.8 DNA damage
leads to stabilisation of p53 resulting from the degradation of
its ubiquitin ligase, MDM2.9 This induces the transcription
of genes whose products trigger cell-cycle arrest, DNA repair
or apoptosis.7 More recently, p53 has been shown to regulate
certain microRNAs (miRNA) by facilitating their transcrip-
tion or modulating the activity of the miRNA biogenesis
machinery.10
MiRNAs are ~ 22 nt RNA molecules which base pair with
target mRNAs resulting in translation inhibition and destabi-
lisation of the bound mRNA.11 These small RNAs are involved
in a range of biological processes and regulate more than half
of all protein-coding genes.11 For example, the transcriptional
activation of the miR-34 family by p53 following DNA
damage12 results in the inhibition of key targets, including
the transcription factor c-Myc which controls genes involved in
cell-cycle progression and cell growth.13,14
In addition to its roles in cell death, p53 has also been
implicated in cell motility,15 and mutant p53 promotes tumour
cell invasion and results in loss of directionality during
migration.16 Cell migration is a complex process and is
controlled by many proteins,17 and the specific role of p53 in
this mechanism is not yet completely understood.
Here, we initially set out to identify new miRNAs associated
with DDR. We found miR-486-5p levels increased ~ 8-fold
following DNA damage, and to our surprise, found the host
gene ANK1 increased ~ 80-fold. We show that both miR-486
and ANK1 are regulated by p53 and that miR-486-5p is
involved in controlling G1/S transition following DNA damage.
On the other hand, ankyrin-1 plays a role in sustaining cell
motility through actin cytoskeleton remodelling upon non-
apoptotic levels of DNA damage. Importantly, we found that
high ANK1 levels correlate with reduced survival in cancer
patients.
Results
Identification of miRNAs upregulated following DNA
damage. To identify miRNAs that change following DNA
damage, we treated the non-tumorigenic MCF10A cell line
with the DNA topoisomerase II inhibitor doxorubicin to induce
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DSBs18 (Figure 1a) and subjected them to small RNA deep
sequencing (Figure 1b). Induction of histone H2A.X phos-
phorylation (γ-H2AX, Ser139) and p53 phosphorylation
(Ser15) confirmed the activation of DDR.4 The dose and
duration of damage were chosen to avoid apoptotic induction,
confirmed by the absence of PARP cleavage (Figure 1a and
Supplementary Figure S1).
Analysis revealed six miRNAs that showed significant
upregulation following damage (Po0.05), all of which showed
42-fold change (Figure 1b). Two miRNAs were downregu-
lated ~ 3-fold (Po0.05) (miR-92a-1-5p and miR-509-3p).
Among the upregulated miRNAs were members of the
miR-34 family, including miR-34c and miR-34a which are
known to be induced following DNA damage;19–21 miR-143-3p
Control (RPM) Dox. (RPM) Fold change p-value
hsa-miR-34c-3p 11.2 0.0005
hsa-miR-486-5p 172.9 0.0007
hsa-miR-34c-5p 1061.3 0.0028
hsa-miR-200a-5p 1.8 0.0029
hsa-miR-34a-3p 16.8 0.0120
hsa-miR-143-3p 14.4 0.0203
hsa-miR-92a-1-5p 91.5 0.0038
hsa-miR-509-3p 15.1
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Figure 1 Identification of microRNAs upregulated following DNA damage. (a) DNA damage was induced in MCF10A cells with doxorubicin (Dox.) at a concentration of
400 nM for 8 h, and was confirmed by western blots for phospho-p53 (Ser15) and γ-H2AX. Absence of cleaved PARP (89 kDa) confirmed cells were not undergoing apoptosis.
Representative western blots shown (n= 3). (b) Small RNA deep sequencing (Illumina) was carried out on total RNA from control and DNA damaged MCF10A cells. MicroRNAs
with a significant fold-change (Po0.05) (n= 3) are shown, with normalised reads displayed as reads per million (RPM). (c) Validation of miR-486-5p upregulation following DNA
damage in MCF10A cells that had been exposed to doxorubicin (400 nM) for 0–48 h. MiR-486-5p levels were quantified via qPCR, as well as miR-34 family members as a
comparison. Values are mean±S.D. (t-test, n= 3, compared with 0 h control), *Po0.05, **Po0.01 and ***Po0.001; NS, not significant. Corresponding western blots are
shown in Figure 2c
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which has been previously implicated in DDR;22 and
miR-200a which has a well-known role in cancer
metastasis23 and DNA damage checkpoint control.24 Impor-
tantly, we also found that miR-486-5p increased by 3.8-fold
following DNA damage and was relatively abundant, suggest-
ing a possible functional role in DDR. MiR-486 is a muscle-
enriched miRNA, but relatively little is known about its
involvement in DDR.25
To validate these results and determine the temporal nature
of miR-486-5p induction, we performed a doxorubicin time-
course using MCF10A cells. MiR-34a and miR-34c were
used as positive controls (Figure 1c). As expected, miR-34a
increased 5.4-fold after 24 h of doxorubicin treatment and
8.0-fold after 48 h. MiR-34c increased 21.5-fold after 24 h of
doxorubicin treatment and remained high at 48 h. A significant
1.5-fold increase in miR-486-5p was detectable as early as 4 h
following doxorubicin exposure, and increased to 8.3-fold after
48 h. We therefore selected miR-486 for further investigation.
The miR-486 host gene ANK1 is also induced following
DNA damage. Approximately half of the 2588 miRNAs in the
human genome are intragenic,26 and there is often a
functional relationship between the miRNA and its host
gene.27 Intragenic miRNAs can be regulated either by the
host gene’s promoter or an independent promoter.28 MiR-486
is located within the last intron of the cytoskeleton adaptor
gene ANK1 (Figure 2a). Therefore we asked if the primary
host gene transcript, ANK1, was also induced following DNA
damage. It was previously shown that miR-486 is controlled
by a p53 promoter located 21.4 kb upstream of ANK1,29 but
to our knowledge no one had previously examined the role of
ANK1 in relation to DNA damage, miR-486 or activation of the
p53 pathway.
Strikingly, we found that ANK1 mRNA was upregulated
16-fold after 8 h of doxorubicin-induced DNA damage
(Figure 2b) and 110-fold after 16 h, which was markedly higher
than the increase in miR-486-5p expression (Figure 1c). To
compare this with a well-known DNA damage-induced tran-
script, we measured mRNA levels of the p53-regulated gene
p21Waf1/Cip1, which showed a 25-fold increase following 16 h of
doxorubicin treatment (Figure 2b). The dramatic induction of
ANK1 mRNA expression levels led us to investigate whether
the ankyrin-1 protein was similarly induced. Indeed, we
observed that the 246 kDa ankyrin-1 protein was induced
~31-fold after 16 h of doxorubicin treatment (Figure 2c), and
~76-fold after 48 h. Importantly, this was restricted to the
canonical ankyrin-1 protein, as the shorter, muscle-enriched
isoform of ankyrin-1 (sAnk1) only increased by ~2-fold after
24 h of treatment (Figure 2c).
Next we examined if ankyrin-1 levels increased following
exposure to other DNA damage inducers. We found that
ionising radiation (IR) exposure induced ankyrin-1 expression
in MCF10A cells (Figure 2d), despite low levels of the DNA
damage marker γ-H2AX. Ankyrin-1 levels were also induced
by the DNA crosslinking reagents cisplatin and mitomycin C
(Figure 2d), and also by a different DNA topoisomerase II
inhibitor, etoposide (Figure 3c). Ultraviolet-C irradiation did not
markedly induce p53 phosphorylation or ANK1 expression,
although high levels of γ-H2AX were observed (Figure 2d).
To examine if the upregulation of ankyrin-1 was specific to
MCF10A cells, we treated another non-tumorigenic cell line,
retinal pigment epithelium (RPE) cells, and also breast cancer-
derived MCF7 cells with etoposide18 (Figure 2e). Both RPE
and MCF7 cells showed a marked increase of ankyrin-1
protein levels following DNA damage. Ankyrin-1 was also
induced by IR exposure in A549 lung carcinoma cells
(Figure 2e).
Taken together, these data demonstrated that ANK1 was
induced in response to various DNA damaging agents in
different cell lines, suggesting an important role for ANK1 in
DDR activation.
ANK1 and miR-486 expression are p53 dependent. To
investigate if the transcription factor p53 was co-regulating
both miR-486 and ANK1 following DNA damage, we depleted
p53 with siRNA prior to doxorubicin treatment (Figure 3a). In
control cells, DNA damage induced miR-486-5p expression
by 11.6-fold and ANK1 expression by 26.5-fold. However,
knockdown of p53 impaired the induction of both miR-486-5p
and ANK1 (Figure 3a).
We then used p53-null cells that harbour either a
doxycycline-inducible wild-type p53 or dominant-negative
mutant p53R175H construct (Figure 3b).30 Upon induction of
wild-type p53 expression with doxycycline, a 3.7-fold induction
of miR-486-5p and a 4.9-fold increase in ANK1 mRNA were
observed. Importantly, ankyrin-1 was also induced at the
protein level (Figure 3b). As expected, expression of mutant
p53R175H did not induce p21Waf1/Cip1. Likewise, both miR-486-
5p and ANK1 were not induced by mutant p53, demonstrating
that only wild-type p53 could induce their expression.
Finally, we asked whether MCF10A cells treated with the
p53 activator nutlin31 could induce ANK1 expression inde-
pendently of DNA damage. In control cells ankyrin-1 was
barely detectable (Figure 3c); however, its expression was
induced following treatment with etoposide or nutlin. The
stabilisation of p53 by nutlin was confirmed by MDM2 and p53
western analysis (Figure 3c).
Taken together, these data strongly suggest that both
miR-486 and ANK1 are induced following DNA damage in a
p53-dependent manner.
miR-486-5p inhibition reverses DNA damage-induced
cell-cycle arrest. Previously it has been reported that
miR-486 expression can inhibit cell growth resulting in
cell-cycle arrest in G1.25,29,32,33 However, these publications
did not examine the role of miR-486 following DNA damage in
conjunction with the role of the host gene ANK1 in cell-cycle
control. To clarify this, we first set out to establish the
individual contributions that increased ankyrin-1 or miR-486-
5p levels had on cells following DNA damage. We used
siRNA to deplete ANK1 and anti-miRs to inhibit miR-486-5p
(Figures 4a and b). We confirmed that siRNA depletion of
ANK1 resulted in the loss of ankyrin-1 induction following
DNA damage (Figure 4a), but did not affect the induction of
miR-486-5p (Figure 4b). Likewise, the inhibition of miR-486-
5p resulted in ablation of the miRNA induction post-DNA
damage (Figure 4b), but did not significantly affect the
induction of ankyrin-1 protein (Figure 4a). Now that we could
separate the contributions of the mRNA and miRNA
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components, we examined the individual effects of ANK1
and miR-486-5p on cell-cycle arrest following DNA damage
(Figure 4c). We used etoposide treatment for the
fluorescence-activated cell sorting (FACS) experiments
because doxorubicin and propidium iodide have overlapping
fluorescence emission wavelengths. In control siRNA-
transfected cells treated with etoposide, we observed a
significant decrease in the G1 population, with a correspond-
ing increase in G2, implying G2/M arrest. Activation of
DDR was confirmed by detection of phospho-ATM, phospho-
p53 and γ-H2A.X (Figure 4a). The depletion of ankyrin-1
following DNA damage (Figure 4a) did not have any effect
on the proportion of cells arrested in G2 (Figure 4c). This
suggests that DNA damage-induced G2 arrest was
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Figure 2 ANK1 is upregulated following exposure to different inducers of DNA damage and in a variety of cell types. (a) Diagram showing the location of miR-486 in relation to
the open reading frame of the cytoskeleton adaptor gene ANK1, as well as the small ankyrin-1 isoform (sAnk1). MiR-486 is located in the intronic region between the last two
exons of the ANK1 gene. (b) MCF10A cells were treated with doxorubicin (dox.) as in Figure 1c, and ANK1 mRNA levels were quantified by qPCR. The p53-regulated p21(Waf1/
Cip1) transcript served as a positive control (n= 3). (c) Representative western analysis of protein samples harvested from cells undergoing DNA damage (n= 3). The ankyrin-1
protein (ANK1) (246 kDa) was quantified (right panel) and normalised to β-actin levels. (d) Ankyrin-1 was induced following ionising radiation (IR, 10 Gy) exposure in MCF10A
cells but not by ultraviolet light-C (UVC, 100 J/m2). Cells were harvested 24 h after IR/UVC exposure. Cisplatin (10 μg/ml) and mitomycin C (300 nM) treatment for 24 h also
induced ankyrin-1. Representative western blots are shown (n= 3). (e) Ankyrin-1 was upregulated following 25 μM etoposide (etop.) treatment for 24 h in retinal pigment
epithelium (RPE) and MCF7 cells, and in A549 cells following IR (5 Gy) exposure where cells were harvested after 6 h. Representative western blots are shown (n= 3). For all bar
charts, values are mean±S.D. (t-test, n= 3, compared with 0 h control), *Po0.05, **Po0.01 and ***Po0.001; NS, not significant
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ANK1-independent. Importantly, the inhibition of miR-486-5p
in cells treated with etoposide resulted in a reduction of cells
in G2/M (Figure 4c).
M-phase arrest induced after nocodazole treatment was
used to confirm that the increase in the G1/S population is not
caused by cells escaping G2/M arrest and re-entering the cell
cycle. Nocodazole-treated cells had a higher proportion of
cells remaining in G1 following miR-486-5p inhibition, with
or without DNA damage (Supplementary Figure S2). This
suggests that miR-486 contributes to G1/S cell-cycle check-
point control.
Ankyrin proteins are composed of three parts:34,35 an
N-terminal membrane-binding region containing multiple
ankyrin repeat domains, a central spectrin-binding region
and a C-terminal regulatory region. Examination of the
ankyrin-1 protein sequence revealed a death domain within
the C-terminus (Supplementary Figure S3). Death domains
are known to interact with components of the apoptosis
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pathway.36We therefore examined if the induction of ankyrin-1
protein could induce apoptosis. We did not observe any
cleaved caspase-3 following either induction or siRNA
depletion of ANK1 (Figure 4a). Similarly, miR-486 expression
in the presence or absence of etoposide treatment did not
induce caspase-3 activation despite previous work, implicat-
ing miR-486 in augmenting DDR.25 To investigate further, we
conducted caspase-3/7 activity assays using cell lysates and
annexin V-FITC staining of live cells, but failed to observe any
increase in caspase activity or apoptosis (data not shown).
Similarly, experiments to test if increased expression of the
death domain-containing ankyrin-1 protein might change the
ability of cells to engage the extrinsic apoptosis pathways37 did
not show any effects on cell death (data not shown).
Taken together, these data suggest miR-486-5p is involved
in maintaining cell-cycle arrest following DNA damage.
However, increased ankyrin-1 levels do not appear to affect
regulation of the cell-cycle or apoptosis in damaged cells.
Owing to the marked induction of ankyrin-1 protein following
DNA damage, we decided to further explore other functions of
ankyrin-1 following DNA damage.
Ankyrin-1 depletion inhibits cell migration and affects the
formation of actin-rich plasma membrane protrusions
following DNA damage. Upon DNA damage, cell migration
is decreased38,39 but is actively maintained through
ATM signalling.40 Ankyrin-1 functions as a membrane
adaptor protein, connecting cell membrane proteins to the
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spectrin-actin cytoskeleton, thus implicating it in cell
migration.41 Moreover, it is well-known that p53 can inhibit
cell motility through regulation of cell morphology, cell
spreading and Rho signalling.15 Given that ANK1 is
controlled by the p53 pathway, we investigated whether
ANK1 plays a role in modulating cell motility. To this end, we
performed wound-healing assays on cells treated with either
control or ANK1 siRNA, with or without etoposide (Figure 5a).
Cells that had not been exposed to DNA damage underwent
wound closure at the same rate in the presence or absence of
ANK1 siRNA (Figures 5b–d). As expected, cells treated
with etoposide did not achieve full wound closure
(Figures 5b–d). Surprisingly, cells that lacked ankyrin-1 were
even more severely affected upon etoposide treatment. For
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example, at 36 h after wound generation, ANK1-expressing
cells treated with etoposide achieved 68.6% scratch wound
closure compared with 38.3% in the absence of ankyrin-1
(Figure 5b). Ankyrin-1 depletion also impaired cell motility in a
transwell migration assay (Supplementary Figure S4). These
data suggested that ankyrin-1 has a role in sustaining cell
movement following DNA damage. Importantly, videos of
wound healing assays (Supplementary Movies) confirmed
impaired movement of ANK1-depleted cells following DNA
damage, showing lamellipodia ruffling which is indicative of
inhibited actin filament turnover.42 Time-lapse videos also
revealed that DNA damaged cells depleted of ankyrin-1
displayed rapid extension and retraction of membrane
protrusions with very little movement of the cell body. The
lack of directional movement of these cells was demonstrated
by cell tracking assays, which depict the movement patterns
of individual cells (Figure 5d).
Intrigued by these observations, we proceeded to examine
the cytoskeleton, specifically looking at the morphology of
actin filaments in response to DNA damage in the presence
or absence of ankyrin-1. Interestingly, it was observed that
control cells treated with etoposide had longer, more prevalent
actin-rich plasma membrane protrusions compared with
etoposide-treated cells following ankyrin-1 depletion
(Figure 6a). Quantification revealed that the removal of
ANK1 by siRNA decreased the proportion of cells with long
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actin protrusions following DNA damage from 27.1% to 8.8%
(Figures 6b–d). These data suggested that ankyrin-1 may play
a role in regulating actin cytoskeleton structure following DNA
damage.
Actin remodelling factors are modulated by ankyrin-
1. As ankyrin-1 appeared to affect actin filament structure
and cell motility, we set out to identify how upregulation of
ankyrin-1 regulates actin remodelling. It is possible that
increased ankyrin-1 levels alone could inhibit actin filament
organisation through increased spectrin-actin binding or,
alternatively, ankyrin-1 could act to modulate actin remodel-
ling signalling pathways.
Since ankyrin repeats (ANK) have been shown to facilitate
nuclear import for some proteins,43 we first investigated the
localisation of ankyrin-1 protein following DNA damage. We
found that the ankyrin-1 protein was present predominantly in
the cytoplasmic compartment (Figure 7a). We then investi-
gated the Rho GTPase signalling pathway, which controls the
remodelling of the actin cytoskeleton.17 To ensure the changes
in this pathway were specific to increased levels of ankyrin-1
and not due to other events triggered by DNA damage, we
overexpressed ANK1 in MCF10A cells (Figure 7b). We
observed a strong reduction in PAK1 levels and also a
reduction in the phosphorylation of the actin-severing protein
cofilin (Figures 7b and c). Both of these proteins are key
regulators of actin remodelling.17 Examination of the tumour
suppressor p27Kip1, which has recently been implicated in cell
migration by regulating RhoA,44 revealed that it too was
significantly reduced upon ANK1 overexpression (Figures 7b
and c).
The impact of ANK1 expression in cancer patients. To
understand the potential clinical relevance of ANK1 expres-
sion levels, we analysed gene expression data from cancer
patients using a database tool.45 This analysis interrogates
gene expression data and identifies correlations with patient
outcome. Since the p53 pathway controls ANK1 expression,
we divided the patient cohort into two groups: the first, where
a positive correlation between TP53 and ANK1 expression is
present, and the second, where it is absent or negative. This
analysis allowed us to ask if the link between TP53 and ANK1
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was significant in a clinical setting. Importantly, we found
that patients with a high positive correlation between TP53
and ANK1 showed increased survival (Supplementary
Figure S5).
Having established the relationship between TP53 and
ANK1 in the clinical setting, we next asked how ANK1
expression alone relates to patient survival. Interestingly, we
found that high ANK1 expression correlated with decreased
survival in lung cancer, breast cancer and CLL (Figure 8a).
Since we have demonstrated ANK1 plays a role in cell motility
following DNA damage (Figures 5 and 6), we hypothesised
that high levels of ANK1 could accelerate the metastasis of
cancer cells that are resistant to chemotherapy. To examine
this we looked at the relationship between ANK1 and genes
associated with DNA repair, such as ATM and CHEK1.
Indeed, we identified that high levels of both ANK1 and either
ATM or CHEK1 have a negative additive effect on survival
(Figure 8b). These data suggest that ANK1 is connected with
the DDR and its expression has clinical significance.
Discussion
Previous work investigating the function of miR-486 demon-
strated roles in skeletal muscle development,32 regulation of
NF-κB signalling46 and the modulation of phosphoinositide-3-
kinase (PI3K)/Akt signalling.47 In this study, we have shown
that both miR-486 and ANK1 are co-regulated by p53 and are
both induced following DNA damage. Previously, miR-486 had
been shown to be DDR induced48 and p53 regulated.29
However, these studies overlooked the induction of its host
gene, ANK1. Our data show that ANK1 is induced to a greater
extent than the embedded miRNA following DNA damage.
Genome-wide ChIP analysis for p53-binding sites has
identified a p53-binding motif upstream of ANK1.49
MiR-486 has been shown to be controlled by the transcrip-
tion factor MRTF-A at a promoter immediately upstream of
exon 39a within the ANK1 gene, which also allows for the
muscle-specific production of sAnk1 (ANK1.5).47,50,51 Con-
currently, miR-486 has also been shown to be regulated by a
p53 promoter upstream of the ANK1 gene in lung cancer.29
Our work shows that p53 controls bothmiR-486 and full-length
ANK1 expression following DNA damage. It is known that the
ANK1 gene is regulated by erythroid transcription factor
GATA-1 and transcription factor NF-E2,52 but its expression in
relation to p53 has never been examined. It is not unreason-
able to assume that the same p53-binding site located 21.4 kb
upstream of ANK1, previously shown to regulate miR-486,29
may control the expression of both transcripts. However, we
cannot rule out the possible usage of other uncharacterised
p53-binding sites.
Previous reports demonstrated that the overexpression of
miR-486 results in inhibition of cell growth and blocks cell-
cycle progression,25,29 but the effect of miR-486 on cell-cycle
arrest following DNA damage has not been examined. We
investigated this using non-tumorigenic MCF10A cells that
arrest at G2/M following DNA damage, and observed that
inhibition of miR-486-5p resulted in a reduction of cells in
G2/M. This suggests that, similar to the miR-34 family,14
miR-486-5p may play a role in the maintenance of cell-cycle
arrest followingDNA damage. Further investigation is required
to identify mRNA targets of miR-486-5p, the repression of
which would facilitate cell-cycle arrest during DDR.
Intriguingly, whereas miR-486-5p leads to the inhibition of
cell-cycle progression, ankyrin-1 appears to play no role
in cell-cycle maintenance, but rather has an effect on actin
remodelling and facilitating cell motility. Indeed, the ankyrin
protein has been implicated in cell migration.53 Ankyrins are
highly conserved adaptor proteins that connect a variety
of membrane-spanning proteins with the spectrin-actin
cytoskeleton.41 As ankyrin-1 has been shown to bind to
TIAM1, which in turn stimulates GDP/GTP exchange activity
on Rac1,53 we looked at a panel of molecular components in
the actin remodelling pathway. We found that overexpression
of ANK1 severely hampered the expression of PAK1, p27Kip1
and phospho-cofilin levels, but had little effect on levels of
ROCK1/ROCK2 or TIAM1. It is known that cofilin, along with
ARP2/3 and profilin, is one of the main effectors of actin
remodelling. Therefore, we speculate that the lack of actin
protrusions and perturbed migratory behaviour in DNA
damaged cells lacking ankyrin-1 may be attributed to
ankyrin-1 levels modulating components of the Rho GTPase
signalling pathway. This ultimately results in impaired cell
motility. The physiological reason for the apparent facilitation
of cell migration as a result of ANK1 upregulation following
DNA damage is currently unclear; however, it is in line with
other previously documented observations.40
In summary, we have shown how p53 can regulate a single
transcript that produces two distinct molecular units with very
different functions: a structural protein to facilitate motility and
a co-expressed miRNA to attenuate cell-cycle progression
following DNA damage. We also implicate a novel role for
ankyrin-1 in the DDR. In line with our findings, a lack of TP53/
ANK1 correlation predicts a poor patient outcome in clinical
data sets. Importantly, we found that higher ANK1 levels alone
correlated with lower tumour-free patient survival in the clinical
setting. Moreover, high expression levels of ANK1 and DNA
repair genes, such as ATM and CHEK1, in combination, are
additive in predicting negative outcome. In light of the role
ANK1 plays in cell motility post-DNA damage, we postulate
that high levels of ANK1 could accelerate the metastasis of
cancer cells that are resistant to chemotherapy. This suggests
that ANK1 expression might potentially be used as a
prognostic marker in patients with specific tumours.
Materials and Methods
Cell culture. MCF10A cells were cultured in DMEM/F12 (Gibco, Grand Island,
NY, USA) with 5% horse serum, 1% glutamine, 20 ng/ml recombinant human EGF
(Peprotech, Rocky Hill, NJ, USA), 10 μg/ml insulin, 500 ng/ml hydrocortisone and
10 ng/ml cholera toxin. MCF7 and A549 cells were cultured in DMEM with 10% fetal
bovine serum (FBS) and 1% L-glutamine. The p53/R175H doxycycline-inducible
H1299 cells were described previously16 and were cultured in DMEM using 10%
tetracycline-free FBS and 1% glutamine. Gene expression of p53/R175H was
induced by culturing cells in 2 μg/ml doxycycline for 48 h. RPE cells were cultured in
DMEM/F12 with 10% FBS, 1% glutamine and 0.16% sodium bicarbonate. All cells
were grown at 37 °C in a 5% CO2 humidified incubator.
DNA damage and p53 induction. DNA damage was achieved using either
25 μM etoposide (24 h) (Cayman, Ann Arbor, MI, USA) in dimethyl suphoxide
(DMSO), 400 nM doxorubicin hydrochloride (0–48 h) (Sigma, St. Louis, MO, USA),
10 μg/ml cisplatin (24 h) (Sigma) or 300 nM mitomycin C (24 h) (Sigma). IR was
produced by an Xstrahl X-Ray irradiator: Xstrahl (Camberley, UK) and ultraviolet
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light was produced using a UV crosslinker CX-2000 (UVP, Upland, CA, USA). The
p53 activator nutlin-3 (Sigma) was prepared in DMSO and used at 10 μM for 24 h.
Western blotting and antibodies. Cells were harvested in RIPA buffer
(150 mM NaCl) and lysates were sonicated for 2.5 min prior to clarification. Total
protein (20–40 μg) was separated on polyacrylamide gels and transferred
onto nitrocellulose membrane, 0.45 μm. All antibodies were used at dilutions
recommended by the manufacturer. Antibodies used were: ANK1 (Novus
Biologicals, Littleton, CO, USA, NBP1-71805) – for detection of endogenous
protein, ANK1 (Atlas Antibodies, Stockholm, Sweden, HPA056953) – for detection of
cloned protein, sAnk1 (Abcam, Cambridge, UK, ab58698) – for detection of the
small isoform, Total p53 (Santa Cruz, Dallas, TX, USA, sc-126), Phospho-p53
(Ser15) (Cell Signalling, Danvers, MA, USA, #9284), MDM2 (Santa Cruz, sc-965),
Total H2A.X (Cell Signalling, #2595), Phospho-histone (γ) H2A.X (Ser139) (Cell
Signalling, #9718), PARP (Cell Signalling, #9542), Β-actin (Sigma, A5441), p21Waf1/
Cip1 (Santa Cruz, sc-397), Phospho-ATM (Ser1981) (Abcam, ab81292), Caspase-3
(Cell Signalling, #9662), GAPDH (Santa Cruz, sc-32233), eIF4G (Cell Signalling,
#2498), Lamin A/C (Santa Cruz, sc-7292), p27Kip1 (Cell Signalling, #3686), PAK1
(Bethyl Laboratories, Montgomery, TX, USA, A301-259AT), Total cofilin (Cell
Signalling, #5175), Phospho-cofilin (Ser3) (Cell Signalling, #3313), ROCK1 (Cell
Signalling, #4035), ROCK2 (Bethyl Laboratories, A300-047A-T), TIAM1 (Bethyl
Laboratories, A300-099AT) and Vinculin (Abcam, ab18058). IR-Dye-labelled
secondary antibodies (LI-COR) were used to detect primary antibodies. Blots were
scanned with a LI-COR laser-based image detector: LI-COR Biosciences, (Lincoln,
NE, USA) and analysed using Image Studio software (v.2.1).
Small RNA library preparation. Total RNA was purified using Trizol reagent
(Invitrogen, Carlsbad, CA, USA). Small RNA libraries were prepared using the
TruSeq Small RNA kit (Illumina, San Diego, CA, USA) with 0.5 μg total RNA.
Libraries were sent to The Genome Analysis Centre (TGAC), Norwich. The small
RNA libraries were checked on a BioAnalyser (Agilent DNA 2100 chip, Agilent,
Santa Clara, CA, USA) and LabChip GX, followed by quantification. Libraries were
pooled and sequenced on the Illumina HiSeq 2500 (Rapid-Run mode, cBot
clustering) platform using 50 bp single end reads.
Bioinformatics analysis of deep sequencing data and accession
numbers. All sequencing files were transformed from FASTQ to FASTA format
and the adaptors were removed by matching the first 8 nt of adaptor sequence
(TGGAATTC). These reads were then then mapped to mature human miRNA
sequences from miRBase version 2054 using PatMaN55 to obtain counts for all
annotated miRNAs in each of the samples. Differentially expressed miRNAs were
called using the edgeR package.56 A P-value of 0.05 was used as a cutoff to
analyse microRNAs that were upregulated following DNA damage. Deep
sequencing data are available from National Center for Biotechnology Information
(NCBI) Sequence Read Archive (SRA) accession SRP064590.
Quantitative PCR and TaqMan assays. MicroRNAs were quantified
using TaqMan assays (Applied Biosystems, Foster City, CA, USA) with 100 ng input
total RNA. MicroRNA and sRNA-specific reverse transcription primer and probe
reagents used were: hsa-miR-486-5p (#001278), hsa-miR-34a-5p (#000426), hsa-
miR-34c-5p (#000428) and U6 snRNA (#001973). SYBR green (Applied
Biosystems) based quantitative PCR (qPCR) was used for mRNA quantification.
Superscript III reverse transcriptase (Invitrogen) was used to convert 1 μg total RNA
to cDNA using random primers. cDNA was used as a template in qPCR with
gene-specific primers: ANK1: forward 5′-TGAAGACGGGAGCCTCGAT-3′ and
reverse 5′-GGGGTCTCCACTTTCACGTT-3′; p21Waf1/Cip1: forward 5′-GGAGAC
TCTCAGGGTCGAAA-3′ and reverse 5′-GGATTAGGGCTTCCTCTTGG-3′ and
GAPDH: forward 5′-AGCCACATCGCTCAGACAC-3′ and reverse 5′-GCCCAATAC
GACCAAATCC-3′.
TheΔΔCT method was used to calculate fold-change between the control sample
and the other conditions using U6 snRNA as an internal control gene for microRNAs
and GAPDH for mRNAs.
Statistical analysis. Where stated, statistical significance was analysed using
the Student’s t-test (two sample, two tailed, unpaired) and expressed as a P-value.
In all bar charts and graphs, error bars represent the standard deviation of relative
values/fold-changes from three experiments. Statistical significance for cancer
patient data analysis was calculated using the relevant bioinformatics tool (see
below).
siRNAs and transfection. SiRNA transfections were performed using
Lipofectamine RNAiMAX (Invitrogen) and Opti-MEM+GlutaMAX (Gibco). The negative
control siRNA used in all experiments was the ON-TARGETplus non-targeting siRNA
#3 (Thermo Scientific, Waltham, MA, USA, D-001810-03-50), (+)5′-UCAGAAAACAUG
UAAACCA(dTdT)-3′, (− )5′-UGGUUUACAUGUUUUCUGA-3′. The p53 targeting
siRNA was custom ordered from Eurofins (Luxembourg City, Luxembourg),
(+)5′-GACUCCAGUGGUAAUCUAC(dTdT)-3′, (− )5′-GUAGAUUACCACUGGAG
UC(dTdT)-3′, and transfected at 50 nM twice over 2 days. The ANK1 targeting
siRNA was a Silencer Select siRNA (Ambion, s1364), (+)5′-AAAUCAGUUUAACA
CCUUA(dTdT)-3′, (− )5′-UAAGGUGUUAAACUGAUUU(dCdA)-3′ and was trans-
fected once at 20 nM.
FACS. For cell-cycle analysis, cells were fixed in ice cold 70% ethanol/30% PBS
and left at −20 °C for 6–12 h. Cells were then washed in PBS and stained with
10 μg/ml propidium iodide and 0.1 mg/ml RNase A in PBS and left at 37 °C for
30 min, followed by overnight incubation at 4 °C. Propidium iodide incorporation into
DNA was measured using the BD FACSCanto II (BD Biosciences, San Jose, CA,
USA) with the 488 nm laser, measuring forward scatter, side scatter and red
fluorescence. 10 000 cells were measured for each experimental condition.
Wound healing assay (scratch assay). MCF10A cells were transfected
with the appropriate siRNA and then treated the following day with either DMSO or
25 μM etoposide for 24 h. Cells were allowed to grow to full confluency in six-well
plates. A linear scratch was made using a 10 μl pipette tip and cell migration into
the wound was monitored for 48 h using a phase contrast time-lapse microscope at
× 5 magnification. Images were taken at three different points along the scratch at
10 min intervals using MetaMorph Microscopy Automation & Image Analysis
Software (v.7.8): Molecular Devices (Sunnyvale, CA, USA). Scratch wound closure
was measured at specific time points along each scratch using the ImageJ software:
National Institutes of Health, (Bethesda, MD, USA). Cell tracking was achieved
using the Manual Tracking plugin on ImageJ.
Immunofluorescence confocal microscopy. Cells were grown on
coverslips at low confluency and transfected with the appropriate siRNA. The
following day cells were treated with either DMSO or 25 μM etoposide for 24 h.
Cells were then fixed using 4% formaldehyde in PBS for 10 min and permbealised
with 0.25% Triton X-100 in PBS for a further 10 min. Cells were blocked in 5% goat
serum and 0.1% Triton X-100 in PBS for 1 h, followed by staining with Alexa Fluor
488 phalloidin (Life Technologies, Carlsbad, CA, USA) according to the manufac-
turer’s instructions. Coverslips were mounted using Vectashield hard set mounting
medium with DAPI (Vector Laboratories, Burlingame, CA, USA). Confocal micro-
scopy was performed using a Zeiss LSM 510 microscope at × 63 magnification,
equipped with ZEN software (Zeiss, Oberkochen, Germany). Only isolated cells (not
in colonies) had their protruding actin processes measured using ImageJ software.
Cytoplasmic and nuclear fractionation. Cells were washed twice in
PBS and pelleted by centrifugation at 250 × g for 2 min, then resuspended in
fractionation buffer (10 mM HEPES pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose,
10% glycerol, 1 mM DTT, 1 × protease inhibitor (Roche, Basel, Switzerland), 10 mM
β-glycerophosphate, 50 mM NaF, 15 μM MG-132), followed by addition of 0.1%
Triton X-100. Cells were incubated on ice for 8 min followed by centrifugation at
1300 × g, 4 °C for 5 min, followed by collection and clarification of the supernatant
(cytoplasmic) fraction. The pellet (nucleus) was washed twice with fractionation
buffer and lysed in RIPA buffer (same volume as cytoplasmic fraction), followed by
sonication for 5 min and clarification. Equal volumes of nuclear and cytoplasmic
lysate were analysed via western blot.
ANK1 cloning and nucleofection. The ANK1 gene was cloned from
ORFeome Collaboration vector BC156401 (Thermo) into pcDNA3.1(+) (Invitrogen)
using primers: Forward: 5′-CGCGGAATTCATGCCCTATTCTGTGGGCTTC-3′ (with
EcoRI restriction site) and Reverse: 5′- CGGCCTCGAGTCACTTGTCGTCATCGT
CTTTGTAGTCGGGGTTGGGTGTCGAGGTG-3′ (with XhoI site and FLAG tag).
PCR was performed using Phusion DNA Polymerase (NEB) in HF buffer with
DMSO. Temperature cycling parameters were: 98 °C for 1 min, followed by four
cycles of: 98 °C – 10 s, 50 °C – 20 s, 72 °C – 5 m 30 s, followed by 25 cycles of:
98 °C – 10 s, 60 °C – 20 s, 72 °C – 5 m 30 s, followed by a final 10 min extension at
72 °C. The entire cloned ANK1 sequence was checked by Sanger sequencing
following cloning. The pcDNA-ANK1-FLAG construct was nucleofected using
programme T-020 (AMAXA nucleofector kit L) (Lonza, Basel, Switzerland) into 1
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million MCF10A cells using 1.5 μg plasmid. Cells were harvested 48 h after
nucleofection.
Datamining of gene expression data. The analyses of translational
relevance of ANK1 have been performed with the BioProfiling.de online datamining
tools45 using publically available clinical gene expression data from the GEO
omnibus repository. The PPISURV57 tool was used to correlate gene expression
data with cancer patient survival. To demonstrate translational relevance of potential
association between ANK1 and DNA damage genes we used the SynTarget tool.
SynTarget estimates the synergy of gene expression of two genes on survival of
cancer patients. Patients in the clinical data sets are split into four groups with
respect to the expression of the ANK1 and CHK1/ATM genes (high–high, high–low,
low–high and low–low). Next, each group is tested versus other samples to find any
statistical differences in survival outcome (i.e. high–high versus others, high–low
versus others and so on).
Determining p53/ANK1 correlation and survival outcome in
cancer patients. In contrast to the standard approach, where patients are
grouped based on high/low expression of a gene, in this case, patients are grouped
based on presence/absence of correlation between p53/ANK1 genes. Namely, in
the first group we selected patients so as to maximise positive correlation of p53/
ANK1, while all the other patients formed the second group. To identify statistical
differences in survival outcome between the two groups of patients, the R statistical
package was used to perform statistical tests and to derive the P-value.
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